Aripiprazole Oral Acceptability Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00101569

Enrollment

Registered

2005-01-13

Start date

2004-03-31

Completion date

2005-03-31

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Interventions

DRUGAripiprazole

Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stable patients currently receiving aripiprazole or other antipsychotic medications.

Design outcomes

Primary

Measure	Time frame
acceptability	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026